2016 Fiscal Year Final Research Report
Therapeutic effects of anti-high mobility group box-1 monoclonal antibody for influenza A virus (H1N1)- induced pneumonia
| Project/Area Number |
15K21184
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Emergency medicine
Pediatrics
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
MORISHIMA Tsuneo 岡山大学, 大学院医歯薬学総合研究科, 特命教授
NISHIBORI Masahiro 岡山大学, 大学院医歯薬学総合研究科, 教授
TSUKAHARA Hirokazu 岡山大学, 大学院医歯薬学総合研究科, 教授
MATSUKAWA Akihiro 岡山大学, 大学院医歯薬学総合研究科, 教授
LIU Keyue 岡山大学, 大学院医歯薬学総合研究科, 助教
YASHIRO Masato 岡山大学, 大学病院, 助教
YAMADA Mutsuko 岡山大学, 大学院医歯薬学総合研究科, 研究員
HATAYAMA Kazuki 岡山大学, 大学院医歯薬学総合研究科, 大学院生
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Keywords | インフルエンザ肺炎 / HMGB-1 / 抗体治療 |
|---|
| Outline of Final Research Achievements |
Provision for an influenza pandemic is an urgent issue. We aimed to evaluate the therapeutic effects of anti-high mobility group box-1 (HMGB1) monoclonal antibody (mAb) treatment on severe pneumonia induced by influenza A virus in mice. Anti-HMGB1 mAb significantly improved the survival rate of mice with severe influenza pneumonia with attenuated histological changes in the lungs. In addition, anti-HMGB1 mAb also improved the survival rate of mice with influenza pneumonia with 50% lethality even with anti-influenza drug administration. There were no adverse effects found by anti-HMGB1 mAb administration.
|
| Free Research Field |
小児集中治療、小児感染症、インフルエンザ
|
